However, clinical trials using DR5-agonistic antibodies, either as monotherapy or combined with chemotherapy or other targeted therapies, have been failed to show benefits in leukemia, although safety profiles have been well documented [17]. This evidence concerns the gene TNFRSF10B and leukemia.